The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...
The Biden administration announced on Friday the selection of the next 15 prescription drugs that will undergo price ...
Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...
More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...
In 2024, drug makers lowered the cost of dozens of common medications to avoid penalties imposed by the American Rescue Plan, Katie Thomas of ...
Axios Boston on MSN1d
Mass. files suit accusing insulin makers of price-gougingMassachusetts is the latest state going after insulin makers and the intermediaries officials accuse of price gouging. Why it ...
BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...
Gov. Newsom committed California to making its own insulin. It’s at least a year behind his schedule
Gov. Newsom in 2020 signed a law allowing California to manufacture its own insulin, an effort to bring down the cost of the ...
Columbus joins the states of Arkansas, California, Kansas, Kentucky, Minnesota and Mississippi and other cities and counties ...
The average price per insulin unit hit a 10-year low in 2024, largely driven by federal actions and voluntary price cuts from drugmakers, according to a Jan. 15 GoodRx report.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback